EyePoint Pharmaceuticals, Inc. Logo

EyePoint Pharmaceuticals, Inc.

Develops sustained drug delivery therapeutics for serious retinal diseases.

EYPT | US

Overview

Corporate Details

ISIN(s):
US74440J1016 (+1 more)
LEI:
Country:
United States of America
Address:
480 PLEASANT STREET, 2472 WATERTOWN

Description

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all EyePoint Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for EyePoint Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for EyePoint Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Aprogen, Inc Logo
Develops and manufactures biologic medicines, including biosimilars and novel drugs.
South Korea
007460
Develops drugs for intractable diseases by regulating oxidative stress and CAFs.
South Korea
293780
Aptamer Sciences Inc Logo
Clinical-stage company developing aptamer-based therapeutics for oncology.
South Korea
291650
Aptorum Group Ltd Logo
Clinical-stage biopharma developing therapeutics for oncology and infectious diseases.
United States of America
APM
Aquestive Therapeutics, Inc. Logo
Pharmaceutical company developing oral film medicines for CNS and allergic reactions.
United States of America
AQST
Arbutus Biopharma Corp Logo
Clinical-stage biopharma company developing a functional cure for chronic Hepatitis B.
United States of America
ABUS
Arcellx, Inc. Logo
A clinical-stage biotech company developing immunotherapies for cancer and autoimmune diseases.
United States of America
ACLX
Arctic Bioscience Logo
Develops pharmaceutical and nutraceutical products from marine membrane lipids.
Norway
ABS
ArcticZymes Technologies Logo
Develops and manufactures novel recombinant enzymes from Arctic marine organisms.
Norway
AZT
Arcturus Therapeutics Holdings Inc. Logo
A commercial-stage mRNA medicines company focused on rare and infectious diseases.
United States of America
ARCT

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.